J. David Enloe Jr.
President and Chief Executive Officer
David Enloe brings nearly 20 years of executive management experience primarily in biotechnology, drug development and GMP Manufacturing. Mr. Enloe joins Ajinomoto Althea Inc. after serving as Head of Lonza’s Viral Therapeutics Business Unit since August 2010. This new business unit was the result of Lonza’s acquisition of Vivante GMP Solutions, a company that Mr. Enloe founded in June, 2009 and where he served as President and CEO until its sale to Lonza AG. Under Mr. Enloe’s leadership, the business experienced rapid expansion, with revenues increasing 500% over a three year period. Preceding Vivante, Mr. Enloe spent 14 years with biotech company, Introgen Therapeutics, joining as its first employee in 1995 and spending several years as Senior Vice President and COO before ultimately being named President and CEO. In addition to helping start the company, Mr. Enloe was an integral part of taking Introgen through a successful IPO in 2000 as well as several other financial dealings. In addition, Mr. Enloe oversaw several large corporate collaborations, as well as the filing of license applications with both the FDA and European regulatory authorities of Introgen’s lead product. Prior to Introgen, Mr. Enloe was in the energy sector in Southeast Asia, the Rocky Mountains, and Texas. Mr. Enloe is a Certified Public Accountant and started his career in public accounting with Arthur Andersen & Co.